Skip Navigation



JAC Advance Access published online on January 23, 2006
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dki477
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
57/3/573    most recent
dki477v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Petersen, P. J.
Right arrow Articles by Bradford, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Petersen, P. J.
Right arrow Articles by Bradford, P. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
Received October 7, 2005
Revised November 30, 2005
Accepted December 12, 2005

Brief report

In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis

Peter J. Petersen 1, Ponpen Labthavikul 1, C. Hal Jones 1 *, and Patricia A. Bradford 1

1 Infectious Disease Discovery Research, Wyeth Research, Pearl River, NY 10965, USA

* To whom correspondence should be addressed.
C. Hal Jones, E-mail: jonesh3{at}wyeth.com


  Abstract

Objectives: This study was undertaken to determine the interaction of tigecycline with 13 select antimicrobial agents against a wide variety of Gram-negative and Gram-positive bacterial isolates.

Methods: Antibiotic interactions were assayed using the chequerboard MIC format and selected synergistic combinations were confirmed using time-kill kinetic analysis.

Results: Microdilution chequerboard analysis of tigecycline in combination with amikacin, ampicillin/sulbactam, azithromycin, ciprofloxacin, colistin, imipenem, levofloxacin, piperacillin, piperacillin/tazobactam, polymyxin B, rifampicin, minocycline and vancomycin resulted in an interpretation of either no interaction or synergy. Time-kill kinetic analysis resulted in an interpretation of no interaction for all but one of the drug combinations that resulted in an interpretation of synergy by the chequerboard analysis. Antagonism was not observed for any combination when assayed by either method.

Conclusions: The lack of antagonism seen with tigecycline combinations in both chequerboard and time-kill kinetic studies is an encouraging outcome, suggesting that tigecycline may prove to be effective in combination therapy as well as in monotherapy.

Keywords: antibiotics; synergy; antagonism; susceptibility.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Microbiol.Home page
J. Lee, G. Patel, S. Huprikar, D. P. Calfee, and S. G. Jenkins
Decreased Susceptibility to Polymyxin B during Treatment for Carbapenem-Resistant Klebsiella pneumoniae Infection
J. Clin. Microbiol., May 1, 2009; 47(5): 1611 - 1612.
[Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
L. A. Arroyo, I. Mateos, V. Gonzalez, and J. Aznar
In Vitro Activities of Tigecycline, Minocycline, and Colistin-Tigecycline Combination against Multi- and Pandrug-Resistant Clinical Isolates of Acinetobacter baumannii Group
Antimicrob. Agents Chemother., March 1, 2009; 53(3): 1295 - 1296.
[Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
K. E. Bowker, A. R. Noel, and A. P. MacGowan
Pharmacodynamics of Minocycline against Staphylococcus aureus in an In Vitro Pharmacokinetic Model
Antimicrob. Agents Chemother., December 1, 2008; 52(12): 4370 - 4373.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
D. E. Karageorgopoulos, T. Kelesidis, I. Kelesidis, and M. E. Falagas
Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence
J. Antimicrob. Chemother., July 1, 2008; 62(1): 45 - 55.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
J. Vouillamoz, P. Moreillon, M. Giddey, and J. M. Entenza
In vitro activities of tigecycline combined with other antimicrobials against multiresistant Gram-positive and Gram-negative pathogens
J. Antimicrob. Chemother., February 1, 2008; 61(2): 371 - 374.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. H. Scheetz, C. Qi, J. R. Warren, M. J. Postelnick, T. Zembower, A. Obias, and G. A. Noskin
In Vitro Activities of Various Antimicrobials Alone and in Combination with Tigecycline against Carbapenem-Intermediate or -Resistant Acinetobacter baumannii
Antimicrob. Agents Chemother., May 1, 2007; 51(5): 1621 - 1626.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
K. N. Agwuh and A. MacGowan
Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines
J. Antimicrob. Chemother., August 1, 2006; 58(2): 256 - 265.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.